Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio

Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced an exclusive licensing and manufacturing agreement with LyoGenesis Plus ("LyoGenesis"), a cGMP ...

Darryl Drake Jr. Named President of Valor as Vector Science and Therapeutics Targets the Performance Medicine Market

Vector Science and Therapeutics Corp. (TSXV: PAIN), a pharmaceutical-grade peptide and precision drug delivery company, today ...

Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the filing of a provisional patent application covering a ...

Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor

Newly Formed Sports Medicine Division Taps Experienced Leader to Build Elite Athlete Network and Distribution Channel MEQUON, Wis., June 8, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp.
Morningstar

Vector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board

Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology MEQUON, Wis., April 30, 2026 ...

Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform

Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less MEQUON, Wis., June 12, 2026 /PRNewswire/ -- Vector ...
Newswire

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations FDA-Registered, cGMP Manufacturing-- MPP operates a modern 35,000 sq. ft.

Valor by Vector Science & Therapeutics: Darryl Drake Jr. Named President of Valor as Vector Science and Therapeutics Targets the Performance Medicine Market

Vector Science and Therapeutics Corp. (TSXV: PAIN), a pharmaceutical-grade peptide and precision drug delivery company, today announced that ...
Morningstar

Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor

MEQUON, Wis., June 8, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board ...